These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 15769897)

  • 21. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
    Jiang J; Paez JG; Lee JC; Bo R; Stone RM; DeAngelo DJ; Galinsky I; Wolpin BM; Jonasova A; Herman P; Fox EA; Boggon TJ; Eck MJ; Weisberg E; Griffin JD; Gilliland DG; Meyerson M; Sellers WR
    Blood; 2004 Sep; 104(6):1855-8. PubMed ID: 15178581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
    Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts.
    Birkenkamp KU; Geugien M; Lemmink HH; Kruijer W; Vellenga E
    Leukemia; 2001 Dec; 15(12):1923-31. PubMed ID: 11753614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.
    Zheng R; Friedman AD; Levis M; Li L; Weir EG; Small D
    Blood; 2004 Mar; 103(5):1883-90. PubMed ID: 14592841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
    Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
    Gerloff D; Grundler R; Wurm AA; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Madan V; Müller-Tidow C; Duyster J; Tenen DG; Niederwieser D; Behre G
    Leukemia; 2015 Mar; 29(3):535-47. PubMed ID: 25092144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
    George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
    Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
    Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
    Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
    Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T
    Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.
    Zheng R; Friedman AD; Small D
    Blood; 2002 Dec; 100(12):4154-61. PubMed ID: 12393674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
    Janke H; Pastore F; Schumacher D; Herold T; Hopfner KP; Schneider S; Berdel WE; Büchner T; Woermann BJ; Subklewe M; Bohlander SK; Hiddemann W; Spiekermann K; Polzer H
    PLoS One; 2014; 9(3):e89560. PubMed ID: 24608088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
    Thiede C; Steudel C; Mohr B; Schaich M; Schäkel U; Platzbecker U; Wermke M; Bornhäuser M; Ritter M; Neubauer A; Ehninger G; Illmer T
    Blood; 2002 Jun; 99(12):4326-35. PubMed ID: 12036858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
    Yanada M; Matsuo K; Suzuki T; Kiyoi H; Naoe T
    Leukemia; 2005 Aug; 19(8):1345-9. PubMed ID: 15959528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FLT3/ITD mutation signaling includes suppression of SHP-1.
    Chen P; Levis M; Brown P; Kim KT; Allebach J; Small D
    J Biol Chem; 2005 Feb; 280(7):5361-9. PubMed ID: 15574429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.
    Scholl S; Krause C; Loncarevic IF; Müller R; Kunert C; Wedding U; Sayer HG; Clement JH; Höffken K
    J Lab Clin Med; 2005 Jun; 145(6):295-304. PubMed ID: 15976757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
    Agrawal S; Koschmieder S; Bäumer N; Reddy NG; Berdel WE; Müller-Tidow C; Serve H
    Leukemia; 2008 Jan; 22(1):78-86. PubMed ID: 17943165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors.
    Minami Y; Kiyoi H; Yamamoto Y; Yamamoto K; Ueda R; Saito H; Naoe T
    Leukemia; 2002 Aug; 16(8):1535-40. PubMed ID: 12145695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.